Private equity investments in health care have grown to over $750 billion in the past decade and include every segment of the US health sector.

Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.

Identifying when and how personal, professional, or social value systems are affected by moral injury can inform efforts to mitigate it.

Lack of training and lack of knowledge can adversely influence a patient’s clinical outcomes.

Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.

Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.

Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.

Even disclosed conflicts of interest can be dangerous in health care settings, but disclosure might not be the panacea many seem to take it to be.

Financial relationships are common, and ethical questions rightly emerge about how conflicts of interest compromise investigators’ approaches to research.